Miyazawa Y, Hori K, Tsuji Y, Sekine Y, et al. The utility of the [-2]pro-prostate-specific antigen level as a prognostic marker in patients with castration-resistant prostate cancer treated with enzalutamide. Int J Urol 2023 May 31. doi: 10.1111/iju.15212.
PMID: 37256915